 <h1>Cetuximab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cetuximab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Serious and potentially fatal infusion reactions may occur and require immediate interruption of the cetuximab infusion and permanent discontinuation. Cardiopulmonary arrest and/or sudden death have been reported in patients with squamous cell carcinoma of the head and neck treated with radiation therapy and cetuximab or platinum-based therapy with 5-fluorouracil and cetuximab. Monitoring of serum electrolytes during and after cetuximab therapy is recommended.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cetuximab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking cetuximab:</p><p>
<i>More common</i>
</p><ul>
<li>Blemishes on the skin or pimples</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>body aches or pain</li>
<li>chills</li>
<li>congestion</li>
<li>cough</li>
<li>deep cracks, grooves, or lines in the skin</li>
<li>difficult or labored breathing</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>rapid weight gain</li>
<li>runny nose</li>
<li>severe dry skin</li>
<li>skin rash</li>
<li>tender, swollen glands in the neck</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trouble with breathing on exertion</li>
<li>trouble with swallowing</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>voice changes</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>black, tarry stools</li>
<li>chest pain</li>
<li>confusion</li>
<li>decreased urination</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>increase in heart rate</li>
<li>lightheadedness</li>
<li>rapid, shallow breathing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sunken eyes</li>
<li>thirst</li>
<li>wrinkled skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>cracked lips</li>
<li>diarrhea</li>
<li>difficulty in swallowing</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>red, irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>stiff neck or back</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cetuximab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>burning, dry, or itching eyes</li>
<li>difficulty having a bowel movement</li>
<li>discharge from the eye</li>
<li>discoloration of the fingernails or toenails</li>
<li>discouragement</li>
<li>excessive tearing</li>
<li>feeling sad or empty</li>
<li>hair loss or thinning of the hair</li>
<li>heartburn</li>
<li>indigestion</li>
<li>irritability</li>
<li>lack or loss of appetite</li>
<li>lack or loss of strength</li>
<li>loss of interest or pleasure</li>
<li>pain</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>sleeplessness</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cetuximab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Acneiform rash (90%), alopecia (21%), skin fissures (19%), nail disorder (16%), skin disorder (15%), acne (14%) </p>
<p><b>Common</b> (1% to 10%): Pruritus</p>
<p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome/toxic necrolysis</p>
<p><b>Frequency not reported</b>: Superinfection of skin lesions</p>
<p><b>Postmarketing reports</b>: Life-threatening/fatal bullous mucocutaneous disease<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiopulmonary arrest and/or sudden death </p>
<p><b>Uncommon</b> (0.1% to 1%): Deep vein thrombosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (66%), nausea (55%), vomiting (41%), anorexia (36%), constipation (30%), stomatitis (26%), dyspepsia (14%), mucositis, dry mouth (12%)</p>
<p><b>Postmarketing reports</b>: Mucosal inflammation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (25%), anemia (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (49%), cough (30%) </p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary embolism, interstitial lung disease<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypomagnesemia (55%), sensory neuropathy (45%), weight loss (21%), peripheral edema (16%), dehydration (15%), severe hypomagnesemia (15%)</p>
<p><b>Common</b> (1% to 10%): Hypocalcemia, anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (56%), fever (29%), chills (16%), taste disturbance (10%)</p>
<p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Frequency not reported</b>: Late radiation toxicity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (14%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Blepharitis, keratitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%)</p>
<p><b>Frequency not reported</b>: Aseptic meningitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Kidney failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Mild or moderate infusion related reactions</p>
<p><b>Common</b> (1% to 10%): Severe infusion related reactions (in some cases fatal)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (13%)</p>
<p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (14%), back pain (16%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): High alanine transaminase (43%), high aspartate transaminase (38%), high alkaline phosphatase (33%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (27%), confusion (18%), anxiety (14%), depression (14%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion reaction (e.g., chills, rigors, dyspnea, tachycardia, bronchospasm, chest tightness, swelling, urticaria, hypotension, flushing, rash, hypertension, nausea, angioedema, pain, sweating, tremors, shaking, drug fever, or other hypersensitivity reaction) (15%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_4">4. Schrag D,  Chung KY,  Flombaum C,  Saltz L "Cetuximab therapy and symptomatic hypomagnesemia." J Natl Cancer Inst 97 (2005): 1221-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about cetuximab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>En Español</li>
<li>9 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cetuximab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Erbitux</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
<li>Head and Neck Cancer</li>
<li>Squamous Cell Carcinoma</li>
<li>Non-Small Cell Lung Cancer</li>
<li>Pancreatic Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cetuximab: intravenous solution</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Acneiform rash (90%), alopecia (21%), skin fissures (19%), nail disorder (16%), skin disorder (15%), acne (14%) </p><p><b>Common</b> (1% to 10%): Pruritus</p><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome/toxic necrolysis</p><p><b>Frequency not reported</b>: Superinfection of skin lesions</p><p><b>Postmarketing reports</b>: Life-threatening/fatal bullous mucocutaneous disease<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiopulmonary arrest and/or sudden death </p><p><b>Uncommon</b> (0.1% to 1%): Deep vein thrombosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (66%), nausea (55%), vomiting (41%), anorexia (36%), constipation (30%), stomatitis (26%), dyspepsia (14%), mucositis, dry mouth (12%)</p><p><b>Postmarketing reports</b>: Mucosal inflammation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (25%), anemia (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (49%), cough (30%) </p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary embolism, interstitial lung disease<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypomagnesemia (55%), sensory neuropathy (45%), weight loss (21%), peripheral edema (16%), dehydration (15%), severe hypomagnesemia (15%)</p><p><b>Common</b> (1% to 10%): Hypocalcemia, anorexia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (56%), fever (29%), chills (16%), taste disturbance (10%)</p><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Frequency not reported</b>: Late radiation toxicity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (14%)</p><p><b>Uncommon</b> (0.1% to 1%): Blepharitis, keratitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%)</p><p><b>Frequency not reported</b>: Aseptic meningitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Kidney failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Mild or moderate infusion related reactions</p><p><b>Common</b> (1% to 10%): Severe infusion related reactions (in some cases fatal)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (13%)</p><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (14%), back pain (16%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): High alanine transaminase (43%), high aspartate transaminase (38%), high alkaline phosphatase (33%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (27%), confusion (18%), anxiety (14%), depression (14%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion reaction (e.g., chills, rigors, dyspnea, tachycardia, bronchospasm, chest tightness, swelling, urticaria, hypotension, flushing, rash, hypertension, nausea, angioedema, pain, sweating, tremors, shaking, drug fever, or other hypersensitivity reaction) (15%)<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Erbitux (cetuximab)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_4">4. Schrag D,  Chung KY,  Flombaum C,  Saltz L "Cetuximab therapy and symptomatic hypomagnesemia." J Natl Cancer Inst 97 (2005): 1221-4</p><h2>More about cetuximab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>En Español</li>
<li>9 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cetuximab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
<li>Head and Neck Cancer</li>
<li>Squamous Cell Carcinoma</li>
<li>Non-Small Cell Lung Cancer</li>
<li>Pancreatic Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>